World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2023. https://covid19.who.int/.  Accessed 27 Feb 2023.

Tortorici MA, Veesler D. Structural insights into coronavirus entry. Adv Virus Res. 2019;105:93–116. https://doi.org/10.1016/bs.aivir.2019.08.002.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yi C, Sun X, Ye J, Ding L, Liu M, Yang Z, et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol Immunol. 2020;17:621–30. https://doi.org/10.1038/s41423-020-0458-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 2020;41:355–9. https://doi.org/10.1016/j.it.2020.03.007.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–78. https://doi.org/10.1016/s0140-6736(20)31604-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603–15. https://doi.org/10.1056/NEJMoa2034577.

Article  CAS  PubMed  Google Scholar 

Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, Andréll J, et al. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6 months after the infection. Med. 2021;2:281–95. https://doi.org/10.1016/j.medj.2021.02.001.

Article  CAS  PubMed  Google Scholar 

Wheatley AK, Juno JA, Wang JJ, Selva KJ, Reynaldi A, Tan H-X, et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun. 2021;12:1162. https://doi.org/10.1038/s41467-021-21444-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD, et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell. 2021;184:169–83. https://doi.org/10.1016/j.cell.2020.11.029.

Article  CAS  PubMed  Google Scholar 

Sokal A, Chappert P, Barba-Spaeth G, Roeser A, Fourati S, Azzaoui I, et al. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell. 2021;184:1201–13. https://doi.org/10.1016/j.cell.2021.01.050.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suthar MS, Zimmerman MG, Kauffman RC, Mantus G, Linderman SL, Hudson WH, et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep Med. 2020;1:100040. https://doi.org/10.1016/j.xcrm.2020.100040.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Australian Government Department of Health. Vaxzevria (AstraZeneca). 2022. https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/approved-vaccines/astrazeneca. Accessed 11 Jul 2022.

Australian Government Department of Health. Comirnaty (Pfizer). 2022. https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/approved-vaccines/pfizer. Accessed 11 Jul 2022.

Australian Government Department of Health. ATAGI recommendations on the use of a booster dose of COVID-19 vaccine. 2022. https://www.health.gov.au/resources/publications/atagi-recommendations-on-the-use-of-a-booster-dose-of-covid-19-vaccine. Accessed 1 Apr 2022.

Chemaitelly H, Ayoub HH, AlMukdad S, Coyle P, Tang P, Yassine HM, et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA1 and BA2 subvariants in Qatar. Nature Communications. 2022;13:3082. https://doi.org/10.1038/s41467-022-30895-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

The New York Times. Tracking coronavirus vaccinations around the world. The New York Times. 2023. https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html. Accessed 3 Feb 2023.

Pharmacuetical Technology. COVID-19 vaccination latest news, daily rates, information and updates. Pharmaceutical Technology. 2023. https://www.pharmaceutical-technology.com/covid-19-vaccination-tracker/. Accessed 3 Feb 2023.

Kim JY, Lim SY, Park S, Kwon J-S, Bae S, Park JY, et al. Immune responses to the ChAdOx1 nCoV-19 and BNT162b2 vaccines and to natural coronavirus disease 2019 infections over a 3-month period. J Infect Dis. 2022;225:777–84. https://doi.org/10.1093/infdis/jiab579.

Article  CAS  PubMed  Google Scholar 

Kang YM, Minn D, Lim J, Lee K-D, Jo DH, Choe K-W, et al. Comparison of antibody response elicited by ChAdOx1 and BNT162b2 COVID-19 vaccine. J Korean Med Sci. 2021;36:e311–e311. https://doi.org/10.3346/jkms.2021.36.e311.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021;398:856–69. https://doi.org/10.1016/S0140-6736(21)01694-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tenbusch M, Schumacher S, Vogel E, Priller A, Held J, Steininger P, et al. Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infect Dis. 2021;21:1212–3. https://doi.org/10.1016/S1473-3099(21)00420-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goel RR, Painter Mark M, Apostolidis Sokratis A, Mathew D, Meng W, Rosenfeld Aaron M, et al (2021) mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374. https://doi.org/10.1126/science.abm0829

Piano Mortari E, Russo C, Vinci MR, Terreri S, Fernandez Salinas A, Piccioni L, et al. Highly specific memory B cells generation after the 2nd dose of BNT162b2 vaccine compensate for the decline of serum antibodies and absence of mucosal IgA. Cells. 2021;10:2541. https://doi.org/10.3390/cells10102541.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sokal A, Barba-Spaeth G, Fernández I, Broketa M, Azzaoui I, de La Selle A, et al. mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity. 2021;54:2893–907. https://doi.org/10.1016/j.immuni.2021.09.011.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hartley GE, Edwards ESJ, O’Hehir RE, van Zelm MC. New insights into human immune memory from SARS-CoV-2 infection and vaccination. Allergy. 2022;77:3553–66. https://doi.org/10.1111/all.15502.

Article  CAS  PubMed  Google Scholar 

Hartley GE, Edwards ESJ, Varese N, Boo I, Aui PM, Bornheimer SJ, et al. The second COVID-19 mRNA vaccine dose enhances the capacity of Spike-specific memory B cells to bind Omicron BA.2. Allergy. 2022;78:855–8. https://doi.org/10.1111/all.15624.

Article  CAS  PubMed  Google Scholar 

Kotaki R, Adachi Y, Moriyama S, Onodera T, Fukushi S, Nagakura T, et al. SARS-CoV-2 Omicron-neutralizing memory B-cells are elicited by two doses of BNT162b2 mRNA vaccine. Science Immunology 2022; 7. https://doi.org/10.1126/sciimmunol.abn8590

Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021;27:1525–9. https://doi.org/10.1038/s41591-021-01449-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276–80. https://doi.org/10.1038/s41586-021-03777-9.

Article  CAS  PubMed  Google Scholar 

Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021;397:2331–3. https://doi.org/10.1016/S0140-6736(21)01290-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garcia-Beltran WF, Lam EC, St Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184:2372–83. https://doi.org/10.1016/j.cell.2021.03.013.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garcia-Beltran WF, St Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022;185:457–66. https://doi.org/10.1016/j.cell.2021.12.033.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021;184:4220–36. https://doi.org/10.1016/j.cell.2021.06.020.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fryer HA, Hartley GE, Edwards ESJ, O'Hehir RE, and van Zelm MC. Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. Biochemical Society Transactions 2022https://doi.org/10.1042/bst20220415

Nextstrain. Genomic epidemiology of SARS-CoV-2 with global subsampling. 2022. https://nextstrain.org/ncov/open/global. Accessed 28 Feb 2022.

World Health Organisation. Weekly epidemiological update on COVID-19 - 24 August 2022. 2022. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---24-august-2022. Accessed 30 Aug 2022. 

Stanford University Coronavirus Antiviral & Resistance Database. SARS-CoV-2 variants genome viewer. Stanford University. 2022. https://covdb.stanford.edu/page/mutation-viewer/#omicron. Accessed 30 Mar 2022.

outbreak.info. Lineage comparison, p. SARS-CoV-2 (hCoV-19) Mutation Reports. 2022. https://outbreak.info/compare-lineages?pango=Omicron&gene. Accessed 30 May 2022.

Stanford University Coronavirus Antiviral & Resistance Database. SARS-CoV-2 Variants. Stanford University. 2022. https://covdb.stanford.edu/page/mutation-viewer/#omicron. Accessed 30 May 2022.

World Health Organisation. Tracking SARS-CoV-2 variants. 2023. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/. Accessed 24 May 2023.

Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, Lehmann C, et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat Med. 2022;28:477–80.